Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 in Combination With Pemetrexed for Metastatic Solid Tumors With MTAP Deletion
NCT07594626Phase 2Recruiting
- Sponsor
- Northwestern University
- Start
- Aug 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MRTX1719 in solid tumor, sponsored by Northwestern University. Primary endpoints: Dose Limiting Toxicity up to 21 days, Incidence of Treatment-Emergent Adverse Events and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07594626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594626.